- authorisedTherapeutic exploratory (Phase II)
Targeting IL-13 in Bullous Pemphigoid: An Investigator-Initiated, Prospective, Multicenter, Proof-of-Concept, Open-Label Pilot Study of Lebrikizumab
This clinical trial is testing a medicine called lebrikizumab (Ebglyss) for people with bullous pemphigoid, a rare condition that causes severe skin blisters and itching. The study looks at whether regular injections over 48 weeks can help clear blisters, calm itching, and reduce the need for strong steroid creams.
Denmark - recruitingPhase II and Phase III (Integrated)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid
This study is testing a new medicine, Dupixent, for a skin condition called Bullous Pemphigoid. We want to see if it helps heal the skin and reduce itching better than current treatments, looking at how safe and effective it is for adults.
France · Poland · Germany - recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
This study looks at a new medicine called efgartigimod for adults with Bullous Pemphigoid. It's an ongoing study to see how safe and effective the medicine is long-term, and how well it helps manage symptoms and improve quality of life.
Bulgaria · Italy · Czechia - not yet recruiting
Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid
Researchers are looking at a new, simpler way to check how severe a skin condition called Bullous Pemphigoid is. This study aims to see if a score called IGA can accurately measure the disease, helping doctors monitor it more easily.
France - authorisedTherapeutic use (Phase IV)
DERMOS study : Influence of dermocorticoids on bone mineral density in patients with bullous pemphigoid.
This study looks at how a strong skin cream, clobetasol propionate, used for a skin condition called bullous pemphigoid, might affect your bone strength. Researchers want to see if using this cream changes your bone density over six months.
France